Topics
Latest
AI
Amazon
Image Credits:Luminate
Apps
Biotech & Health
mood
Image Credits:Luminate
Cloud Computing
Commerce
Crypto
Luminate founders (from left) Aaron Hannon, Barbara Oliveira, and Martin O’Halloran.Image Credits:Luminate
Enterprise
EVs
Fintech
A prototype version of the Lilac gloves and boots in use.Image Credits:Luminate
Fundraising
contraption
Gaming
Government & Policy
ironware
Layoffs
Media & Entertainment
Meta
Microsoft
seclusion
Robotics
surety
Social
distance
Startups
TikTok
Transportation
Venture
More from TechCrunch
event
Startup Battlefield
StrictlyVC
Podcasts
video
Partner Content
TechCrunch Brand Studio
Crunchboard
Contact Us
Luminate’swearable machine for haircloth retention during chemotherapy treatment is getting the testing it needs for commercial release , but the startup is already see ahead to its next finish : powering at - home cancer forethought . A newfangled $ 15 million support round should help it make a start on it .
The startup is one of the most strange , but promising , ones we covered in 2021 . The pitch sounds a bit sci - fi : a helmet called Lilythat hoi polloi undergoing chemotherapy article of clothing to prevent hair loss , which is a common side effect of the treatment .
It sounds charming , but it ’s in reality quite simple : By applying even imperativeness across the entire scalp , the helmet block off capillaries and prevents the toxic chemo cocktail from reaching the patient ’s haircloth follicles . This was sufficient , CEO and founder Aaron Hannon excuse , to prevent 75 % of people from lose their hair in the troupe ’s first examination .
“ We ’ve had patients stop four to 12 chemo treatments and keep a full head of hair . There ’s been incredible feedback about how it ’s changed their experience of going through treatment , ” Hannon said . The mental testing also unwrap that there are few , if any , safety , comfort , or gimmick issue , and that in fact wearing the helmet for longer improves outcomes . That ’s about as good a result as you may expect , though with only a handful of patients , Luminate now has to pace it up for its U.S. unveiling .
“ The next step is a multi - midway study in the U.S. for FDA headway there . New York , Florida , potentially Ohio — we ’re openly enrolling sites that want to trial the technology , ” Hannon say . The subject would require 85 patients for seven to eight month , potentially start in November .
Luminate has other irons in the fire beyond the laborious FDA approval process . Its success in this oncology - adjacent country has shown its team new opportunities to facilitate people in discourse .
Hannon said that the team identified chemo - have neuropathy — basically , face damage at the extremities — as another common side effect that the same atmospheric pressure technology can potentially reduce . It ’s basically like a precision compressing windsock or glove ; indeed those garment are already used with some burden , he order , but the wearables they ’re working on do it in a predictable , precise way .
Join us at TechCrunch Sessions: AI
Exhibit at TechCrunch Sessions: AI
Being so conceptually close to Lily , Lilac ( as they ’re calling the glove - boot combo ) makes sense to go after as Luminate ’s next medical twist ; a lot of the employment is already done . “ It took us maybe two years to go from pre - clinical to completing a first patient trial show efficaciousness for Lily ; it took us one yr for Lilac , ” Hannon said .
It also correspond into a greater , farseeing - condition strategy and ambition : to help wreak cancer tutelage to the home .
Oncology is highly subordinate on especial equipment ordinarily locate in care center . But for many patient , go to the infirmary is difficult , time - consuming , even irritating . Any guardianship that can be done in the home ought to be , but chemotherapy is impractical due to how it ’s distribute . Not only that , but pre - infusion blood work and paperwork mean a two - hr session might take four or five all told .
Yet with Cancer the Crab diagnosing coming in the beginning in life and intervention lengths growing , care mall may not have the seats uncommitted to cover as many people as they ’d like to in a timely way ( and delay has hurtful effects ) . Other than building out more chemo seats at great cost , what can be done ?
“ Our large-minded visual sense right now is we want to help deliver Cancer the Crab treatments at abode , ” Hannon said . Though this is still a ways out , he explained that the fellowship is work on on a way for patients to do blood work , pre - infusion judgment , and actual chemo handling themselves .
This is nowhere near ready , of grade , and Hannon was clean-cut the company is n’t rushing toward anything . But it is “ building something to let [ patients ] do the blood draw themselves , then look at how to do lowly complexity , safe chemo at place . We ’re await at something like an automobile - injector to get at live hypodermic embrasure . ”
Just as home tending for other chronic and acute diseases has become more common , Luminate hopes that home cancer discussion will produce more realistic as caller invest in it .
Luminate will be spend out of a new funding round , a $ 15 million Series A led by Artis Ventures , with participation by Metaplanet , Lachy Groom , 8VC , SciFounders , and Faber , along with some individuals .
The near terminus , Hannon said , will see the society building out its U.S. clinical mien , include teams for examination , training , marketing , and so on as the clinical test here progress .
